TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
Bram De LaereSteffi OeyenMarkus MayrhoferTom WhitingtonPieter-Jan van DamPeter Van OyenChristophe GhyselJozef AmpePiet OstWim DemeyLucien HoekxDirk SchrijversBarbara BrouwersWillem LybaertEls G EveraertDaan De MaeseneerMichiel StrijbosAlain BolsKaren FransisNick BeijeInge E de KruijffAnja BrouwerDirk GoossensLien HeyrmanGert G Van den EyndenAnnemie RuttenJurgen Del FaveroMattias RantalainenPrabhakar RajanStefan SleijferAnders UllénJeffrey YachninHenrik GronbergSteven J Van LaereJohan LindbergLuc Y DirixPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
In an all-comer cohort, tumor burden estimates and TP53 outperform any AR perturbation to infer prognosis.See related commentary by Rebello et al., p. 1699.